United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

January 19, 2024

https://www.globenewswire.com/news-release/2024/01/18/2812039/0/en/United-States-Food-Drug-Administration-FDA-Grants-Mesoblast-Rare-Pediatric-Disease-Designation-for-Revascor-Rexlemestrocel-L-in-Children-With-Congenital-Heart-Disease.html

REVASCOR Increases Size of Left Heart Chamber and Improves Surgical Outcomes in Children with Hypoplastic Left Heart Syndrome: Results Published in Journal of Thoracic and Cardiovascular Surgery Open

Read more at globenewswire.com

Related news for (MESO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.